{"filings":[{"id":1083804,"accession_number":"0001104659-26-074575","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2026-06-16T20:05:35+00:00","items":["8.01"],"status":"ready","headline":"Altimmune plans HQ move from Gaithersburg, MD to Morristown, NJ","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Announced on June 16, 2026, relocation expected later this year.","New 5-year lease with annual rent of approximately $300,000.","Move to biopharma hub in NJ to support talent attraction in hybrid model.","Company expects long-term cost efficiencies from the relocation.","Headquarters change from 910 Clopper Road, Gaithersburg to Morristown."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50161,"accession_number":"0001326190-26-000037","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2026-05-13T11:34:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.6M ($0.18 loss per share) vs $19.6M ($0.26) in Q1 2025; R&D $16.2M, G&A $8.1M.","Cash, equivalents and short-term investments $332M at Mar 31, 2026; $535M at Apr 30, 2026 after $225M public offering.","Initiation of PERFORMA Phase 3 MASH trial planned for H2 2026; topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE Phase 2 ALD enrollment completion Q3 2026.","Pemvidutide received Breakthrough Therapy Designation for MASH; EASL presentations on May 28, 2026 including 48-week IMPACT data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92136,"accession_number":"0001104659-26-048552","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Altimmune raises ~$211M in public offering to fund MASH Phase 3 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 64.25M common shares at $3.00/share and pre-funded warrants for up to 10.75M shares.","Net proceeds of ~$211.2M after underwriting discounts and expenses; offering closed April 24, 2026.","Proceeds to fund pemvidutide Phase 3 MASH trial and pre-commercial activities.","Common stock warrants exercisable at $3.00/share for 5 years or 45 days after Phase 3 data announcement.","Warrants not listed on Nasdaq; beneficial ownership limits of 4.99% or 9.99% apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92135,"accession_number":"0001326190-26-000027","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Altimmune shareholders approve doubling authorized shares to 400M, re-elect all directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock increased from 200M to 400M via certificate of amendment, approved by 63.7M for vs. 24.2M against.","All 9 director nominees elected; broker non-votes of 35.9M on each. Highest votes for Jerome Durso at 47.6M.","Ratification of Ernst & Young as auditor passed with 85.0M for, 1.8M against, 1.5M abstain.","Say-on-pay advisory vote passed with 39.9M for, 12.0M against, 0.5M abstain.","Amendment to 2019 ESPP approved to increase reserve from 403,500 to 1,108,827 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102740,"accession_number":"0001326190-26-000013","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune ends FY2025 with $274M cash; FDA breakthrough for MASH; Phase 3 planned 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments: $274M at Dec 31, 2025; ~$340M after $75M offering and $8M ATM in Jan 2026.","FY2025 net loss $88.1M ($1.00/share); Q4 net loss $27.4M ($0.27/share).","Pemvidutide granted FDA Breakthrough Therapy Designation for MASH; Phase 3 trial planned in 2026.","Topline data from RECLAIM Phase 2 trial in alcohol use disorder expected Q3 2026.","Jerry Durso appointed CEO; previously CEO of Intercept Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102739,"accession_number":"0001326190-26-000008","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Altimmune sets 2026 annual meeting for April 16; proposal deadline Feb 13","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for April 16, 2026; record date is March 13, 2026.","Stockholder proposals for inclusion in proxy must be received by February 13, 2026.","Director nominations under bylaws and universal proxy rule due by February 13 and February 15, 2026, respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102738,"accession_number":"0001326190-26-000006","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Altimmune raises ~$75M in registered direct offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 12.4M shares and pre-funded warrants for 4.6M shares at $4.40/share; gross proceeds ~$75M.","Closing expected Jan 29, 2026; Titan Partners acted as sole placement agent.","Pre-funded warrants exercisable at $0.001, no expiration, 9.99% beneficial ownership limit.","Directors and officers subject to 30-day lock-up agreements with customary exceptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118972,"accession_number":"0001104659-25-122724","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Altimmune reports positive 48-week IMPACT data; FDA agrees on Phase 3 path for pemvidutide","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pemvidutide 1.8 mg reduced ELF by -0.58 (p<0.0001) and LSM by -3.97 (p<0.001) vs placebo at 48 weeks.","Weight loss of 7.5% (1.8 mg, p<0.0001) vs 0.2% placebo; no plateau at 48 weeks; AE discontinuation 1.2% vs 3.5%.","Proportion achieving both ELF ≥0.5 reduction and LSM ≥30% reduction: 32.4% (1.8 mg) vs 3.2% placebo (p<0.0001).","End-of-Phase 2 FDA meeting on Dec 11 aligned on Phase 3 design; FDA open to AIM-MASH AI tool; plan to evaluate 2.4 mg dose.","Altimmune raised ~$54.6M net from ATM sales of 13.5M shares after Sep 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118971,"accession_number":"0001104659-25-117144","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Altimmune CEO Vipin Garg to step down Jan 1, 2026; Chairman Jerome Durso named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vipin Garg transitions from President/CEO to advisor through June 30, 2026; remains on board until Jan 31, 2026.","Jerome Durso, current Chairman and former Intercept CEO, becomes President and CEO effective Jan 1, 2026.","Durso receives annual base salary of $725,000, target bonus 60% of base, and equity grants of 633,700 RSUs and 1,824,400 stock options.","Garg will receive severance: 12 months base salary, COBRA subsidy, continued equity vesting through separation date.","Altimmune expects End-of-Phase 2 FDA meeting this quarter and 48-week IMPACT data before year-end for pemvidutide in MASH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118970,"accession_number":"0001326190-25-000067","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Altimmune enters $200M ATM equity distribution agreement with Leerink Partners; terminates prior $150M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered November 2025 Agreement with Leerink Partners for ATM offering of up to $200M common stock.","Sales agent Leerink receives 3% commission on gross proceeds of shares sold under the program.","Prior February 2025 ATM program (up to $150M) terminated effective November 6, 2025 without penalties.","Shares sold through Nasdaq Global Market under Rule 415(a)(4) at the company's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118969,"accession_number":"0001326190-25-000055","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Altimmune Q3 net loss $19M ($0.21/sh); cash $210.8M; debt facility upsized to $125M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $210.8M, up 60% from Dec 2024; net loss $19.0M vs $22.8M year ago.","Hercules loan amended to $125M; drew additional $20M at close; interest-only period extended to 30 months.","Phase 2b IMPACT 48-week MASH data expected before year end; End-of-Phase-2 FDA meeting scheduled Q4 2025.","RECLAIM AUD trial enrollment completed early; topline results expected in 2026. RESTORE ALD trial initiated.","Appointed CMO (Dr. Arbet-Engels), CCO (Richardson), and CLO (Abrams) to executive team."],"consensus_eps_estimate":-0.2843,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118968,"accession_number":"0001326190-25-000053","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Altimmune appoints Christophe Arbet-Engels as CMO; Dr. Scott Harris to retire as Senior Strategic Advisor by Feb 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Scott Harris stepped down as CMO effective Oct 1, 2025; will serve as Senior Strategic Advisor until retirement on Feb 28, 2026.","Christophe Arbet-Engels, MD, PhD joined as CMO effective Oct 1, 2025.","Transition Agreement provides Harris continued salary, benefits, equity vesting, and FY2025 bonus eligibility subject to release and compliance.","Harris's stock option exercise period extended to 12 months after separation date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135517,"accession_number":"0001326190-25-000050","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Altimmune shareholders elect all 10 director nominees; say-on-pay passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Jerome Durso received highest \"for\" votes (20.6M), Philip Hodges lowest (14.7M).","Say-on-pay proposal passed with 14.9M for (68.2%), 6.7M against (30.6%), and 267K abstentions.","Ratification of Ernst & Young as FY2025 auditor passed with 48.9M for, 1.4M against, 1.4M abstain.","Broker non-votes on director elections and say-on-pay totaled 29.9M shares (58% of quorum).","Proposal to authorize meeting adjournment passed with 33.7M for vs. 16.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135516,"accession_number":"0001558370-25-011145","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune reports Q2 2025 net loss of $22.1M; positive pemvidutide MASH data reinforces differentiation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $183.1M (up 39% from Dec 2024); net loss $22.1M ($0.27/sh) vs $24.6M ($0.35) Q2 2024.","Pemvidutide achieved up to 59.1% MASH resolution without worsening fibrosis, up to 34.5% fibrosis improvement, and up to 6.2% weight loss at 24 weeks.","New cT1 imaging data shows mean decreases of 145-148 ms (p<0.001), potentially class-leading in MASH trials.","End-of-Phase 2 FDA meeting targeted for Q4 2025; full 48-week data expected Q4.","Jerry Durso appointed Chairman; Mitchel Sayare remains director as part of board succession."],"consensus_eps_estimate":-0.3262,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152507,"accession_number":"0001326190-25-000037","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Altimmune's pemvidutide Phase 2b MASH trial hits primary endpoint; 59.1% resolution vs 19.1% placebo (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MASH resolution without worsening fibrosis: 59.1% (1.2mg) and 52.1% (1.8mg) vs 19.1% placebo (p<0.0001).","Fibrosis improvement not significant on primary, but AI analysis showed 30.6% achieving ≥60% reduction (p<0.001).","Weight loss of 5.0% (1.2mg) and 6.2% (1.8mg) vs 1.0% placebo (p<0.001); trajectory not plateauing at 24 weeks.","AE-related discontinuations <1.2% in pemvidutide arms vs 2.4% placebo; no SAEs related to study drug."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152506,"accession_number":"0001326190-25-000031","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Altimmune gets $100M Hercules facility, Q1 cash $150M, MASH data expected Q2 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $100M term loan from Hercules; $15M funded at closing, $25M more in 2025 subject to milestones.","Interest-only for 24 months (extendable to 42); maturity June 1, 2029; no warrants.","Q1 net loss of $19.6M ($0.26 loss per share) vs $24.4M loss in Q1 2024.","Cash, equivalents & short-term investments $150M as of Mar 31, 2025; R&D expense $15.8M.","Top-line IMPACT Phase 2b MASH data expected Q2 2025; Phase 2 AUD/ALD trials expected Q2/Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171328,"accession_number":"0001326190-25-000024","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Altimmune to pursue two new indications for pemvidutide: AUD and ALD, Phase 2 trials starting Q2/Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 AUD trial for pemvidutide targeting moderate to severe AUD; ~100 subjects, 24 weeks, endpoints include heavy drinking days.","Phase 2 ALD trial for pemvidutide targeting obesity and ALD; ~100 subjects, 48 weeks, endpoints include liver stiffness and biomarkers.","Both Phase 2 trials are randomized, double-blind, placebo-controlled designs.","Altimmune expects to begin the AUD trial in Q2 2025 and the ALD trial in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171327,"accession_number":"0001326190-25-000011","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Altimmune posts Q4 net loss $23.2M; CMO to retire; pemvidutide MASH data on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $23.2M ($0.33/share) vs $31.6M in Q4 2023 (incl $12.4M impairment); FY2024 net loss $95.1M ($1.34/share).","Cash, cash equivalents and short-term investments $131.9M at Dec 31, 2024.","CMO Dr. Scott Harris will retire effective Feb 28, 2026; company to search for successor.","Top-line data from Phase 2b IMPACT MASH trial expected Q2 2025; IND cleared for two additional indications with Phase 2 trials mid-2025.","Board adds Teri Lawver (ex-Dexcom, J&J) and Jerry Durso (ex-Intercept CEO, Sanofi)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":20000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171326,"accession_number":"0001326190-25-000003","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Altimmune appoints former Dexcom CCO Teri Lawver and ex-Intercept CEO Jerry Durso to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded by two to ten; Lawver and Durso appointed effective Feb 24, 2025.","Lawver, former Dexcom EVP/CCO and J&J Worldwide VP Immunology, brings 30 years pharma/commercial experience.","Durso, ex-CEO of Intercept Pharmaceuticals and 22-year Sanofi vet, led rare liver disease franchise and acquisition.","Each director received initial option for 69,800 shares and $40,000 annual cash retainer.","Appointments support late-stage development and pre-commercial transition for pemvidutide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188319,"accession_number":"0001326190-24-000053","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Altimmune reports pemvidutide Phase 1b MASLD data: LFC reduced up to 68.5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pemvidutide reduced liver fat content (LFC) by up to 68.5% from baseline over 12 weeks in 94 MASLD patients.","Total cholesterol decreased by up to 12.2% and triglycerides by up to 44.6% after 12 weeks of treatment.","Presented at AASLD The Liver Meeting from a 12-week Phase 1b trial in overweight/obese MASLD subjects.","Subjects received once-weekly subcutaneous pemvidutide (1.2mg, 1.8mg, 2.4mg) or placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188318,"accession_number":"0001326190-24-000047","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q3 net loss $22.8M; IMPACT enrollment done, FDA obesity plan set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.8M ($0.32/share) vs $20.7M ($0.39/share) in Q3 2023.","Cash, equivalents and short-term investments total $139.4M as of Sept 30, 2024.","Completed enrollment in Phase 2b IMPACT trial for MASH; top-line data expected Q2 2025.","FDA agreed on Phase 3 obesity program design; IND submissions for up to three additional indications planned.","Appointed Greg Weaver as CFO on November 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188317,"accession_number":"0001326190-24-000046","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Altimmune names Greg Weaver CFO, with $475k salary and 225k option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Weaver appointed CFO effective Nov 11, 2024; previously CFO at atai Life Sciences.","Employment terms: annual salary $475k, target bonus 40%, sign-on option for 225k shares and 75k RSUs.","Andrew Shutterly transitions from Interim CFO to Corporate Controller.","Weaver led $225M IPO at atai Life Sciences and has 25+ years of biotech finance experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204793,"accession_number":"0001326190-24-000042","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Altimmune Announces Stockholder Voting Results from 2024 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees were elected, with Mitchel Sayare receiving 21,231,279 votes for and 660,730 withheld, and broker non-votes of 21,784,295.","Ratification of Ernst & Young as auditor passed with 43,204,496 votes for, 315,411 against.","Advisory say-on-pay proposal passed with 13,663,909 votes for, 7,992,177 against, and 21,784,295 broker non-votes.","Proposal to authorize adjournment for proxy solicitation passed with 26,771,350 votes for, 16,249,120 against.","Total shares voted: 43,676,304 out of 71,070,951 outstanding, representing 61.5% quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204792,"accession_number":"0001326190-24-000036","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Altimmune director David Drutz will not stand for re-election at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Drutz, M.D. notified the Board that he will not stand for re-election at the 2024 Annual Meeting of Shareholders.","Drutz will continue as a director until the date of the Annual Meeting; his decision is not due to any disagreement with the company.","The Board thanked Dr. Drutz for his service; no replacement has been announced as he will not stand for re-election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204791,"accession_number":"0001326190-24-000027","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q2 net loss $24.6M; pemvidutide MASH Phase 2b topline due Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments totaled $164.9M as of June 30, 2024.","Net loss for Q2 2024 was $24.6M ($0.35 per share) vs. $16.1M ($0.32 per share) in Q2 2023.","Phase 2b IMPACT trial of pemvidutide in MASH enrollment progressing; topline data expected Q1 2025.","End-of-Phase 2 FDA meeting for obesity program expected late Q3 2024 to discuss Phase 3 design.","Phase 2 MOMENTUM obesity trial showed up to 15.6% weight loss at 48 weeks and class-leading lean mass preservation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221640,"accession_number":"0001326190-24-000022","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Altimmune CFO Richard Eisenstadt dies unexpectedly; Andrew Shutterly named acting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Eisenstadt, CFO, passed away unexpectedly on June 24, 2024.","Andrew Shutterly appointed acting CFO effective June 25, 2024; previously Corporate Controller since Feb 2023.","Company has initiated a search for a permanent replacement CFO.","Shutterly joined Altimmune in Oct 2020 as Assistant Controller; prior roles at Meso Scale Diagnostics and Deloitte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221639,"accession_number":"0001326190-24-000016","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune reports Q1 2024 net loss $24.4M; cash $182.1M; pemvidutide milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.4M ($0.34/share) vs $20.1M ($0.40) in Q1 2023; R&D expense $21.5M on pemvidutide and HepTcell winddown.","Cash, equivalents & short-term investments $182.1M as of March 31, 2024.","Phase 2b MASH trial (IMPACT) enrollment ongoing; top-line results expected Q1 2025.","End-of-Phase 2 FDA meeting for pemvidutide obesity program expected late Q3 2024.","MOMENTUM Phase 2 data showed 74.5% weight loss from fat, 25.5% from lean mass; visceral fat preferentially reduced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":5000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241191,"accession_number":"0001326190-24-000006","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Altimmune reports Q4 net loss $31.6M; positive pemvidutide body composition data; HepTcell discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $31.6M ($0.54/share) for Q4 2023, including $12.4M impairment for discontinued HepTcell program.","Cash $198.0M; body composition: 74.5% weight loss from fat, 25.5% from lean mass on pemvidutide.","MOMENTUM: 15.6% mean weight loss at 48 weeks on 2.4 mg pemvidutide; >30% achieved ≥20% weight loss.","IMPACT Phase 2b MASH trial enrollment ongoing; topline 24-week data expected Q1 2025.","HepTcell development stopped; overall response in Phase 2 insufficient to warrant further advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258656,"accession_number":"0001326190-23-000050","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Altimmune reports Phase 2 obesity trial: 15.6% mean weight loss with pemvidutide 2.4 mg at Week 48","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean weight loss of 15.6% on 2.4 mg dose vs 2.2% placebo; near-linear trajectory at end of treatment.","Over 30% of subjects achieved ≥20% weight loss on 2.4 mg; 83.9% achieved ≥5% weight loss.","Robust reductions in serum lipids and blood pressure without cardiac safety imbalances; zero MACE events.","Discontinuation rates higher at higher doses: 19.6% (2.4 mg) vs 6.2% placebo; most due to GI AEs in first 16 weeks.","Only one drug-related SAE (vomiting at 2.4 mg); nausea/vomiting predominantly mild to moderate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258655,"accession_number":"0001326190-23-000044","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q3 net loss $0.39/sh; cash $140.8M; obesity trial readout Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.7M ($0.39/sh) vs $23.5M ($0.48) in Q3 2022.","Cash, equivalents & short-term investments $140.8M as of Sep 30, 2023.","Top-line 48-week MOMENTUM Phase 2 obesity trial data expected Q4 2023; 391 subjects randomized.","HepTcell Phase 2 CHB top-line results anticipated Q1 2024; ~80 subjects enrolled.","Pemvidutide granted Fast Track for NASH; IMPACT Phase 2b enrollment ongoing; results Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":389000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275961,"accession_number":"0001326190-23-000040","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Altimmune 2023 annual meeting results: all director nominees elected, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 director nominees elected; highest vote for was 21.9M, lowest 19.4M.","Say-on-pay advisory vote passed: 16.8M for, 5.2M against, 12.4M broker non-votes.","Stockholders selected 1-year frequency for future say-on-pay votes (21.6M for 1-year).","Ernst & Young ratified as auditor for FY2023 with 34.3M for, 153K against.","Adjournment proposal authorized with 27.7M for vs 6.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275960,"accession_number":"0001326190-23-000033","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q2 net loss $16.1M; pemvidutide obesity trial data expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.1M ($0.32/share) vs $20.1M ($0.42/share) in Q2 2022.","Cash, equivalents & short-term investments totaled $160.0M as of June 30, 2023.","R&D expenses $13.3M, G&A $4.8M for the quarter.","Top-line 48-week MOMENTUM Phase 2 obesity trial results expected Q4 2023.","Enrollment commenced in IMPACT Phase 2b NASH trial; top-line data expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":27000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293588,"accession_number":"0001326190-23-000025","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune reports Q1 net loss $20.1M; pemvidutide NASH trial initiation mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.1M ($0.40/share) vs $19.4M ($0.44/share) in Q1 2022; R&D expenses $17.2M.","Cash $165.8M at March 31, 2023; MOMENTUM obesity trial 48-week top-line results expected Q4 2023.","Pemvidutide 24-week data: 10.7% (2.4mg) and 9.4% (1.8mg) mean weight loss; ~50% achieved ≥10% loss.","IMPACT Phase 2b NASH trial (~190 subjects) to start mid-2023; top-line results expected Q1 2025.","HepTcell Phase 2 CHB trial fully enrolled (~80 subjects); top-line results expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":21000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314220,"accession_number":"0001326190-23-000020","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Altimmune appoints former GSK executive Catherine Sohn to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Catherine Sohn, Pharm.D., appointed to Altimmune's Board effective March 23, 2023.","Dr. Sohn currently serves on boards of Jazz Pharma, Axcellea Health, and Maze Therapeutics.","She was formerly SVP Worldwide Business Development at GSK's Consumer Healthcare division.","Received initial option award for 47,000 shares and annual cash retainer of $40,000.","CEO Vipin Garg says her experience in peptide therapeutics for obesity and liver disease will be valuable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314219,"accession_number":"0001326190-23-000017","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Altimmune reports positive Week 24 interim data from Phase 2 obesity trial; pemvidutide up to 10.7% mean weight loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24; p < 0.001 vs placebo.","In subjects ≤115 kg baseline (75% of cohort), mean weight loss reached 11.9% at 2.4 mg dose.","~50% achieved ≥10% weight loss and ~20% achieved ≥15% at 1.8 mg and 2.4 mg doses.","Phase 1b diabetes trial: 7.7% mean weight loss at 2.4 mg dose; no SAEs or discontinuations.","GI AEs mostly mild/moderate; lower doses used without titration; one SAE at 2.4 mg (nausea/vomiting)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314218,"accession_number":"0001326190-23-000003","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q4 2022 net loss $21.7M; cash $184.9M; pemvidutide obesity interim readout expected March 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2022 was $21.7M ($0.43 per share) vs $23.9M ($0.57) in Q4 2021; revenue negligible.","Cash, cash equivalents and short-term investments totaled $184.9M at December 31, 2022.","R&D expenses $19.2M in Q4 2022, including $13.4M for pemvidutide and $1.9M for HepTcell.","MOMENTUM Phase 2 obesity trial 24-week interim readout expected in March 2023; Phase 2b NASH trial initiation expected mid-2023.","HepTcell Phase 2 enrollment >90% complete; data readout expected first half 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":-68000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332653,"accession_number":"0001326190-22-000016","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Altimmune reports positive 24-week pemvidutide NAFLD trial: >75% liver fat reduction, 7.2% weight loss at 1.8 mg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 1.8 mg dose, mean relative liver fat reduction 75.2%; 53.8% achieved normalization (≤5% LFC).","Mean weight loss of 7.2% (placebo-adjusted 6.0%) in non-diabetic subjects at 1.8 mg dose.","Significant ALT declines: ≥17 IU/L reduction in subjects with baseline ALT ≥30 IU/L across all doses.","cT1 response (≥80 ms reduction) achieved in 75% (1.8 mg) and 100% (2.4 mg) of evaluated subjects.","Pemvidutide well tolerated; 3 serious/severe AEs unrelated to drug; no significant ALT elevations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332652,"accession_number":"0001326190-22-000010","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q3 net loss $23.5M, cash $201.9M; pemvidutide NAFLD data mid-Dec, obesity interim Q1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.5M ($0.48 per share) vs $33.5M loss YoY; revenue minimal at ~$0.","Cash, equivalents & short-term investments totaled $201.9M at September 30, 2022.","Topline 24-week data from Phase 1b NAFLD trial expected mid-December 2022.","Interim 24-week readout from Phase 2 MOMENTUM obesity trial (~160 subjects) expected Q1 2023.","Enrollment complete in Phase 1b type 2 diabetes trial; data readout expected Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":42000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350112,"accession_number":"0001326190-22-000007","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Altimmune shareholders elect all 8 director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All director nominees elected: votes ranged from 19.7M to 23.9M for; broker non-votes 12.6M on each.","Ernst & Young ratified as auditor for 2022: 36.4M for, 103K against, 89K abstain.","Say-on-pay advisory vote passed with 17.5M for, 6.5M against, 68K abstain, 12.6M broker non-votes.","Adjournment authorized: 26.1M for, 10.3M against, 179K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350111,"accession_number":"0001558370-22-014392","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Altimmune Phase 1b pemvidutide: 68.5% liver fat reduction, 4.9% weight loss at 12 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 1.8 mg dose, relative liver fat reduction of 68.5%; 94.4% of subjects achieved ≥30% reduction.","Mean weight loss of 4.9% in non-diabetic subjects (placebo-adjusted 4.7%) at 1.8 mg dose.","55.6% of subjects at 1.8 mg achieved liver fat normalization (≤5%).","No serious or severe adverse events; 2 discontinuations due to GI intolerance.","Serum ALT declined >17 IU/L in subjects with baseline ALT ≥30 IU/L; no clinically significant ALT elevations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350110,"accession_number":"0001558370-22-013169","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q2 net loss $20.1M ($0.42/share); cash $184.8M; pemvidutide Phase 1b data mid-Sept","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.1M ($0.42 per share) for Q2 2022 vs $24.8M ($0.60) in Q2 2021, which included $8.1M impairment.","Cash, equivalents, and short-term investments $184.8M at June 30, 2022.","R&D expenses $16.0M in Q2 2022, up from $13.3M, primarily on pemvidutide development.","Pemvidutide Phase 1b obesity/NAFLD topline data expected mid-September 2022; Phase 2 MOMENTUM interim analysis (160 subjects) expected Q1 2023.","HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; data expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":40000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367240,"accession_number":"0001558370-22-008420","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q1 net loss $19.4M ($0.44/share); cash $180.0M; key pemvidutide data readouts Q3/Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.4M ($0.44 per share) vs $14.9M ($0.38) in Q1 2021; R&D expense $15.1M.","Cash, cash equivalents and restricted cash totaled $180.0M at March 31, 2022.","Pemvidutide Phase 2 MOMENTUM obesity trial enrolling ~320 subjects; interim 24-week data expected Q4 2022.","Phase 1b NAFLD trial enrollment completed; 12-week liver fat and weight loss data expected Q3 2022.","HepTcell Phase 2 chronic hepatitis B trial continuing; data readout expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":32000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386611,"accession_number":"0001558370-22-003610","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune reports Q4 2021 net loss of $23.9M ($0.57/share); cash $190.3M; pemvidutide trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.9M ($0.57 per share) vs $10.6M ($0.29) in Q4 2020; R&D expense doubled to $20.2M on pemvidutide development.","Cash, equivalents and short-term investments of $190.3M at Dec 31, 2021; revenue $3.3M vs $2.3M.","Pemvidutide Phase 1b NAFLD trial >90% enrolled; topline data expected Q3 2022.","Phase 2 MOMENTUM obesity trial (48 wks) initiation expected Q1 2022; interim data at 24 wks in Q4 2022.","HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; readout expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404544,"accession_number":"0001104659-21-151231","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2021-12-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Altimmune terminates Lonza manufacturing agreement for AdCOVID program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Master Services Agreement with Lonza Houston Inc. dated November 5, 2020.","Associated SOW provided for dedicated manufacturing suite for AdCOVID clinical/commercial supply.","Termination effective December 17, 2021, following prior discontinuation of AdCOVID program (June 29, 2021)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404543,"accession_number":"0001104659-21-148822","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2021-12-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Altimmune appoints Richard Eisenstadt as CFO effective Dec 31, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Brown resigns as CFO effective Dec 31, 2021 to pursue other opportunities; no disagreement.","Richard Eisenstadt appointed CFO effective Dec 31; annual salary $425,000, target bonus 40%, signing bonus $120,000.","Eisenstadt receives 150,000 stock options and 50,000 RSUs; options vest 25% at one year, balance over 36 months.","Eisenstadt previously CFO at Aytu BioPharma and Neos Therapeutics; raised over $340M in financings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404542,"accession_number":"0001558370-21-015281","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q3 net loss $33.5M; pemvidutide shows liver fat reduction to undetectable levels","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.5M ($0.81 per share) for Q3 2021, up from $17.8M in Q3 2020.","Cash and short-term investments totaled $199.9M at Sept 30, 2021; revenue fell to $0.2M from $2.9M.","Phase 1 pemvidutide data: mean weight loss up to 10.3% at 1.8 mg at week 12 without dose titration.","MRI-PDFF analysis in 5 subjects with hepatic steatosis showed liver fat fell to undetectable levels within 6 weeks (≥90% reduction).","Phase 2 obesity and NASH trials expected to start in 2022; IND for obesity by year-end 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":1132698.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423535,"accession_number":"0001193125-21-284839","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2021-09-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Altimmune Phase 1 pemvidutide shows 10.3% mean weight loss at 1.8 mg; NASH IND cleared","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean weight loss of 10.3% at 1.8 mg dose vs. 1.6% placebo; 100% of subjects lost ≥5%.","No discontinuations due to adverse events; side effects mild-to-moderate, no dose titration needed.","FDA cleared IND for NASH; 12-week NAFLD liver fat trial to start soon.","Phase 2 obesity trial (48-week) planned for H1 2022; diabetes trial expected Q4 2021.","Favorable trends in blood pressure, lipids, HOMA-IR; ketone bodies rise supports glucagon mechanism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423534,"accession_number":"0001104659-21-119390","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2021-09-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Altimmune say-on-pay fails; director Gill gets 41% withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay proposal failed: 10.44M against vs 8.32M for, plus 9.68M broker non-votes.","Director John M. Gill reelected with 11.03M for and 7.78M withhold (41% of votes cast).","All other director nominees received >15M for votes; auditor Ernst & Young ratified with 28.43M for.","Adjournment proposal passed with 18.51M for, 9.79M against.","Approximately 72% of outstanding shares represented at the meeting, forming a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423533,"accession_number":"0001558370-21-011129","cik":1326190,"company_name":"Altimmune, Inc.","ticker":"ALT","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Altimmune Q2 net loss $24.8M; ALT-801 Phase 1 data expected Sept 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $24.8M ($0.60/shr) vs $16.8M ($0.94/shr) prior year; revenue $0.1M down from $0.7M.","Cash, equivalents & investments $217.9M; raised $18.2M net via ATM in Q2.","Recorded $8.1M impairment on construction-in-progress for terminated COVID-19 vaccine program.","ALT-801 Phase 1 12-week data readout on three dose cohorts expected September 2021.","IND for NASH on track for Q3 2021; obesity IND planned Q4 2021; Phase 2 trials targeted early 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":975139.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":598008020.5369127,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}